Le Lézard
Classified in: Health, Science and technology
Subjects: SVY, CFG

Competition Bureau makes recommendations for empowering Canadian health care providers in the digital era


GATINEAU, QC, Nov. 24, 2022 /CNW/ - In its latest market study report, the Competition Bureau provides recommendations on how to improve the ways health care providers work within Canada's public health system.

Empowering health care providers in the digital era, is the third and final report published as part of the Bureau's digital health care market study. The in-depth study examined how pro-competitive policies can foster innovation and bring about greater choice and access to digital health care services for Canadians.

The study found that digital health care is not being used to its full potential in Canada. In 2021, only 14% of Canadians had visited their provider virtually. Meanwhile more than 70% of physicians believe that virtual care improves patient access and enables both quality and efficient care. (sources: Canada Health Infoway; Virtual Care Taskforce)

The final report makes three recommendations to Canadian governments and policymakers to enable health care providers to take advantage of the forces of competition:

  1. Review existing health care provider payment models to support the appropriate use of digital health care.
  2. Implement licensing frameworks that allow providers, where appropriate, to practice beyond provincial and territorial borders to improve digital health care delivery.
  3. Review and modernize policies to facilitate the effective uptake of digital health care.

Empowering health care providers to use the best available digital technologies will lead to lower costs, better health care services, and improved patient outcomes. It will also spur innovation and the development of new products within the health care industry.

While the pandemic encouraged advancements in digital health care, governments across Canada must ensure that rules and regulations evolve quickly to strengthen the health care system.

Quote

"To foster competition in the digital future, Canada's public health care policy needs to be modernized. By facilitating greater adoption of digital health care solutions, Canadians can benefit from increased health care access, lower costs, and better health outcomes."

Matthew Boswell
Commissioner of Competition

Quick facts
Related products

Empowering health care providers in the digital era ? part 3 

Associated links

Background: The Competition Bureau's digital health care market study
Unlocking the power of health data? part 1
Improving health care through pro-competitive procurement policy ? part 2

For general enquiries, please contact:

Enquiries | Complaints

Stay connected:

Twitter | Facebook | LinkedIn | YouTube | RSS Feed | Email Distribution List

The Competition Bureau, as an independent law enforcement agency, ensures that Canadian businesses and consumers prosper in a competitive and innovative marketplace.

SOURCE Competition Bureau


These press releases may also interest you

at 02:22
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024 First Quarter 2024 Total revenue increased 19 per cent, 20 per cent at constant exchange rates, (CER)1, to SEK 6,256 M (5,239)Haematology revenue...

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...



News published on and distributed by: